Real-World BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) Testing Trends by Race for Patients with Metastatic Prostate Cancer (mPC) from 2015 to 2024 in the Community Oncology Setting in the United States (US)
Author(s)
Helen Latimer, MPH, Lisa Herms, PhD, Zhaohui Su, PhD, Robert Reid, MD, Jessica Paulus, ScD;
Ontada, Boston, MA, USA
Ontada, Boston, MA, USA
OBJECTIVES: The introduction of poly-ADP ribose polymerase inhibitors (PARPis) has led to updated practice guidelines recommending BRCA1/2 testing in patients diagnosed with mPC. These targeted therapies have demonstrated improved survival for patients with BRCA1/2-mutant PC. However, despite higher rates of PC in Black men, prior studies have observed disparities in testing rates due to barriers in access. To better understand this gap, this real-world analysis evaluated BCRA1/2 testing trends by race among patients with mPC within a large network of US community practices.
METHODS: This was a retrospective, observational study utilizing structured data from an oncology-specific electronic health records database within The US Oncology Network and non-Network practices. Adult patients diagnosed with mPC from January 2015 to December 2024 were included. Evidence of testing for BCRA1/2 was evaluated within 30 days of metastatic diagnosis.
RESULTS: The study included 23,553 patients. The majority of patients were White (n=18,967; 80.5%), followed by Black (n=3,059, 13.0.%), and other races (n=1,527; 6.5%). Most patients were 65 years or older (18,957; 80.5%) and had de novo metastatic disease (n= 17,432; 74.0%). BCRA1/2 testing rates per year were approximately 1% from 2015-2019 and began rapidly increasing from 2020 (6.3%), with the highest rate observed in 2023 (14.0%). Testing rates were similar among Black (8.0% to 13.8%) and White patients (6.0% to 13.0%) from 2020 to 2022. In 2023 and 2024, White patients had slightly higher testing rates (14.4% and 10.7%) than Black patients (11.4% and 9.3%).
CONCLUSIONS: In recent years, BRCA1/2 testing rates have substantially increased in the community oncology setting, coinciding with the availability of PARPis, and access to biomarker testing remains a priority for patients with mPC. Furthermore, despite the known racial disparities in PC, it is encouraging that stratification by race showed similar testing rates between White and Black patients, although additional investigation is warranted.
METHODS: This was a retrospective, observational study utilizing structured data from an oncology-specific electronic health records database within The US Oncology Network and non-Network practices. Adult patients diagnosed with mPC from January 2015 to December 2024 were included. Evidence of testing for BCRA1/2 was evaluated within 30 days of metastatic diagnosis.
RESULTS: The study included 23,553 patients. The majority of patients were White (n=18,967; 80.5%), followed by Black (n=3,059, 13.0.%), and other races (n=1,527; 6.5%). Most patients were 65 years or older (18,957; 80.5%) and had de novo metastatic disease (n= 17,432; 74.0%). BCRA1/2 testing rates per year were approximately 1% from 2015-2019 and began rapidly increasing from 2020 (6.3%), with the highest rate observed in 2023 (14.0%). Testing rates were similar among Black (8.0% to 13.8%) and White patients (6.0% to 13.0%) from 2020 to 2022. In 2023 and 2024, White patients had slightly higher testing rates (14.4% and 10.7%) than Black patients (11.4% and 9.3%).
CONCLUSIONS: In recent years, BRCA1/2 testing rates have substantially increased in the community oncology setting, coinciding with the availability of PARPis, and access to biomarker testing remains a priority for patients with mPC. Furthermore, despite the known racial disparities in PC, it is encouraging that stratification by race showed similar testing rates between White and Black patients, although additional investigation is warranted.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HPR146
Topic
Health Policy & Regulatory
Topic Subcategory
Health Disparities & Equity
Disease
SDC: Oncology, SDC: Reproductive & Sexual Health